ISB News

The Other Malaria: Finding New Targets for a Vaccine Against Plasmodium vivax

Warhol style Plasmodium

A new report in PLOS Neglected Tropical Diseases describes the results of an international collaboration led by researchers at ISB and Seattle’s Center for Infectious Disease Research (CIDResearch). We used mass spectrometry-based proteomics to identify nearly 2,000 proteins present in Plasmodium vivax parasites, one of the Plasmodium species that cause the disease malaria in humans. The work was done on parasites dissected from mosquito salivary glands, parasites that were in the form that is transmitted from mosquitoes to humans. Because parasite proteins can potentially be recognized by the body’s immune system, the proteins we have identified are promising targets for new vaccines against malaria.

Read More

Related Articles

  • Andrea Varela-Stokes

    ISB’s Moritz Lab Lands NIH Grant to Study Lyme Disease

    ISB’s Moritz Lab has received research funding totaling nearly $525,000 from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health to develop “novel peptide based biomarkers for Lyme disease diagnostics.”

    Read More
  • ISB’s proteomics research in the spotlight

    Microsoft Research recently deployed a video crew to come to ISB to speak with our researchers about proteomics and sharing peptide data. A story featuring the video was published on the Microsoft Research blog.

    Read More
  • Reconstructing 'Ötzi' the Iceman’s last meal

    Members of the Moritz lab, as part of an international consortium centered in Bolzano Italy, reports this week in Cell, “Current Biology”, a multi-omic approach to identify the stomach contents and microbiome of the 5300 year old Mummy, Oetzi, the Iceman from the Oetzal Alps on the Austrian/Italian border.

    Read More
Show More Articles